{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HSV-1&page=2",
    "query": {
      "condition": "HSV-1",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HSV-1&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T05:34:03.231Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04917887",
      "title": "Long-Term Follow-up Protocol",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa",
        "Recessive Dystrophic Epidermolysis Bullosa",
        "Dominant Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Krystal Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-05-25",
      "completion_date": "2028-05-25",
      "has_results": false,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-07-23T05:34:03.231Z",
      "location_count": 3,
      "location_summary": "Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida",
      "locations": [
        {
          "city": "Rancho Santa Margarita",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04917887"
    },
    {
      "nct_id": "NCT05084430",
      "title": "Study of Pembrolizumab and M032 (NSC 733972)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "M032",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2022-02-25",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-07-23T05:34:03.231Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05084430"
    },
    {
      "nct_id": "NCT01017185",
      "title": "Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Head and Neck Cancer",
        "Squamous Cell Carcinoma, Skin",
        "Carcinoma of the Breast",
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "HF10",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takara Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2009-08",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2019-05-23",
      "last_synced_at": "2026-07-23T05:34:03.231Z",
      "location_count": 5,
      "location_summary": "The Bronx, New York • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01017185"
    },
    {
      "nct_id": "NCT00157703",
      "title": "G207 Followed by Radiation Therapy in Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "G207",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediGene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2005-05",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2008-12-16",
      "last_synced_at": "2026-07-23T05:34:03.231Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00157703"
    },
    {
      "nct_id": "NCT02092233",
      "title": "A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Herpes"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Luminex Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1963,
      "start_date": "2014-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-07-10",
      "last_synced_at": "2026-07-23T05:34:03.231Z",
      "location_count": 3,
      "location_summary": "Springfield, Massachusetts • Albuquerque, New Mexico • Burlington, North Carolina",
      "locations": [
        {
          "city": "Springfield",
          "state": "Massachusetts"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Burlington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02092233"
    },
    {
      "nct_id": "NCT02062827",
      "title": "Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Glioblastoma Multiforme",
        "Progressive Glioblastoma Multiforme",
        "Anaplastic Astrocytoma or Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "M032 (NSC 733972)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2013-11-25",
      "completion_date": "2027-09",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-07-23T05:34:03.231Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02062827"
    },
    {
      "nct_id": "NCT02272855",
      "title": "A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "HF10 plus Ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takara Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2014-04-30",
      "completion_date": "2018-08",
      "has_results": false,
      "last_update_posted_date": "2018-09-26",
      "last_synced_at": "2026-07-23T05:34:03.231Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Portland, Oregon + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Bethlehem",
          "state": "Pennsylvania"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02272855"
    },
    {
      "nct_id": "NCT06126744",
      "title": "Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent High Grade Glioma"
      ],
      "interventions": [
        {
          "name": "MVR-C5252",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2024-06-11",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-07-23T05:34:03.231Z",
      "location_count": 2,
      "location_summary": "New York, New York • Durham, North Carolina",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06126744"
    },
    {
      "nct_id": "NCT03661541",
      "title": "Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HSV",
        "Herpes Labialis"
      ],
      "interventions": [
        {
          "name": "Squaric Acid Dibutyl Ester",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Squarex, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2017-03-02",
      "completion_date": "2017-10-25",
      "has_results": true,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-07-23T05:34:03.231Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03661541"
    },
    {
      "nct_id": "NCT01225341",
      "title": "Botulinum Toxin A for Herpes Labialis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Herpes Labialis"
      ],
      "interventions": [
        {
          "name": "onabotulinumtoxinA",
          "type": "DRUG"
        },
        {
          "name": "Bacteriostatic normal saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "DeNova Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-08",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2020-12-21",
      "last_synced_at": "2026-07-23T05:34:03.231Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01225341"
    }
  ]
}